Abstract |
Cycle control and tolerance were studied in a group of 55 female volunteers, who took during 42 consecutive days a modern low-dose oral contraceptive: gestodene 75 micrograms/ethinylestradiol 30 micrograms (Minulet). During these 42 days, 96% of the women experienced no breakthrough bleeding and 81% of the women experienced no spotting or breakthrough bleeding. When the findings of this study are compared with the findings of an earlier study with also a seven-week cycle but with other oral contraceptives, it can be concluded that Minulet offered an excellent cycle control.
|
Authors | H Kornaat, M H Geerdink, J W Klitsie |
Journal | Contraception
(Contraception)
Vol. 45
Issue 2
Pg. 119-27
(Feb 1992)
ISSN: 0010-7824 [Print] United States |
PMID | 1559335
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Contraceptives, Oral, Combined
- Norpregnenes
- Femovan
- Ethinyl Estradiol
|
Topics |
- Adolescent
- Adult
- Contraceptives, Oral, Combined
(pharmacology, standards)
- Dose-Response Relationship, Drug
- Ethinyl Estradiol
(pharmacology, standards)
- Female
- Humans
- Menstrual Cycle
(drug effects)
- Norpregnenes
(pharmacology, standards)
- Patient Compliance
- Time Factors
|